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Metabolic Syndrome and Benign Prostatic Hyperplasia: Evidence 
of a Potential Relationship, Hypothesized Etiology, and Prevention
Firas Abdollah, Alberto Briganti, Nazareno Suardi, Fabio Castiglione, Andrea Gallina, 
Umberto Capitanio, Francesco Montorsi
Department of Urology, San Raffaele Hospital, Università Vita-Salte, Urological Research Institute (URI), Milan, Italy
Benign prostatic hyperplasia (BPH) is highly prevalent in older men and causes sub-
stantial adverse effects on health. The pathogenesis of this disease is not totally clear. 
Recent reports have suggested a possible relationship between metabolic syndrome 
(MetS) and BPH. Single components of MetS (obesity, dyslipidemia, hypertension, and 
insulin resistance) as well as the syndrome itself may predispose patients to a higher 
risk of BPH and lower urinary tract symptoms (LUTS). This may stem from changes 
in insulin resistance, increased autonomic activity, impaired nitrergic innervation, in-
creased Rho kinase activity, pro-inflammatory status, and changes in sex hormones 
that occur in association with MetS. However, the exact underlying mechanisms that 
regulate the potential relationship between MetS and BPH/LUTS still need to be 
clarified. Increased physical activity and dietary strategies may help in decreasing the 
incidence of MetS and its impact on BPH/LUTS. However, differences in the definitions 
used to address the examined predictors and endpoints preclude the possibility of arriv-
ing at definitive conclusions. 
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is highly prevalent in 
older men [1]. Histologically, BPH is characterized by the 
presence of nonmalignant, unregulated overgrowth of the 
prostate gland. Clinically, BPH may be associated with 
lower urinary tract symptoms (LUTS) secondary to the en-
suing prostate enlargement. About 60% of men aged ＞50 
years have histologic evidence of BPH. This prevalence in-
creases to 80% in patients aged ≥70 years [1]. Currently, 
BPH is the fourth most prevalent disease in men aged ＞50 
years [2]. 
　Despite the high prevalence of BPH and the socio-
economic burden related to its treatment [3], the patho-
genesis of BPH is not well understood. In the past two deca-
des, an increasing number of reports (Table 1) have sug-
gested a possible relationship between BPH/LUTS and 
several metabolic disturbances, known collectively as the 
metabolic syndrome (MetS). MetS is a disease process asso-
ciated with defective insulin-mediated glucose uptake, 
which is becoming an increasingly prevalent problem 
worldwide [4,5]. MetS involves a constellation of abnor-
malities including obesity, dyslipidemia, hypertension, 
and insulin resistance, with subsequent development of 
hyperinsulinemia and impaired glucose metabolism. 
Several definitions of MetS have been proposed by various 
organizations [6]. The Adult Treatment Panel III defi-
nition is the one used most today because it incorporates 
the key concepts of MetS and relies on routinely available 
clinical parameters (Table 2) [7].
　The aim of the current report was to summarize and crit-
ically review the available literature that addresses the po-
tential relationship between BPH/LUTS and MetS. More-
over, we aimed to clarify the underlying mechanisms that 
may link these two pathologic conditions and the changes 
in lifestyle that may decrease their prevalence.Korean J Urol 2011;52:507-516
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TABLE 1. Summary of the most relevant reports that addressed the relationship between benign prostatic hyperplasia/lower urinary
tract symptoms and the metabolic syndrome and/or its components: obesity, dyslipidemia, hypertension, and insulin resistance
Author Year
Number of 
patients
Risk factor/s
OR (95% 
Confidence Interval)
p-value Endpoint/s
Seitter and 
  Barrett-Connor [33]
Giovannucci et al [8]
Hammarsten and 
  Högstedt [14]
Michel et al [88]
Hammarsten and 
  Högstedt [4]
Meigs et al [34]
Dahle et al [9]
Joseph et al [15]
Rohrmann et al [85]
Rohrmann et al [29]
Seim et al [11]
Nandeesha et al [23]
Parson et al [10]
1992
1994
1998
2000
2001
2001
2002
2003
2004
2005
2005
2006
2006
929
25,892
158
9,856
307
1,019
 502
 708
2,797
2,372
21,694
88
422
Body mass index
  (≥26.8 vs. ＜24.4 kg/m
2)
Waist circumference
Type II DM
Hypertension
Waist circumference
HDL-cholesterol
Plasma fasting insulin
Metabolic syndrome 
DM
Type II DM
Treated hypertension
Obesity
Dyslipidaemia
Plasma fasting insulin
Metabolic syndrome
Body mass index
  (29-50 vs. 18-24 kg/m
2)
Waist-hip ratio
  (0.98-1.17 vs 0.73-0.90)
Systolic blood pressure
  (133-183 vs. 78-114)
Diastolic blood pressure
  (85-110 vs. 54-72)
DM
Body mass index 
  (＞23.4 vs. ＜19.5 kg/m
2)
Waist-hip ratio
  (＞0.92 vs. ＜0.85%)
Fasting insulin 
  (＞9.7 vs. ＜5.8)
Body mass index
  (≥30 vs. ＜25 kg/m
2)
Hypertension
DM
Body mass index 
  (≥30 vs. ＜25 kg/m
2)
Metabolic syndrome
Metabolic syndrome 
  (specific definition)* 
Hypertension 
Body mass index 
  (35-39 vs. ＜25 kg/m
2)
Waist-hip ratio
  (≥0.94 vs. ＜0.85%)
DM
Fasting insulin
HDL-cholesterol 
LDL-cholesterol 
Body mass index
  (≥35 vs. ＜25 kg/m
2)
Fasting plasma glucose 
  (＞104 vs. ＜90 ng/dl)
0.9 (0.6-1.4)
2.4 (1.4-4.0)
2.0 (1.5-2.7)
Direct relationship
Direct relationship
Direct relationship
Direct relationship
Direct relationship
Direct relationship
1.1 (1.0-1.1)
Direct relationship
Direct relationship
Direct relationship
Direct relationship
Direct relationship
Direct relationship
0.8 (0.5-1.2)
0.9 (0.6-1.5)
0.7 (0.4-1.1)
1.0 (0.6-1.6)
1.5 (0.8-2.7)
1.5 (0.7-2.6)
2.0 (1.1-3.8)
2.2 (1.2-4.1)
1.1 (0.8-1.7)
1.5 (1.1-2.1)
2.0 (1.4-2.9)
1.25 (0.7-2.2)
1.2 (0.8-1.7)
1.8 (1.1-2.9)
1.8 (1.2-2.6)
1.4 (1.1-1.9)
1.3 (1.2-1.5)
1.3 (1.1-1.5)
Direct relationship
Direct relationship
Inverse relationship
3.5 (1.5-8.6)
2.0 (1.1-3.8)
-
＜.001
＜.001
＜.001
＜.001
＜.001
＜.001
＜.001
＜.001
-
＜.001
＜.001
＜.001
＜.001
＜.001
＜.001
-
-
-
-
-
0.1
0.06
0.03
-
-
-
0.3
-
-
-
-
-
＜.001
＜.001
＜.001
0.01
0.03
Prostatectomy for BPH
Prostatectomy for BPH
Frequent urinary symp-
toms among men without 
prostatectomy
Prostate gland volume
Annual BPH growth rate
LUTS
Annual BPH growth rate
LUTS
LUTS
Moderate-severe LUTS
LUTS
 
LUTS
LUTS
BPH
Prostate gland volumeKorean J Urol 2011;52:507-516
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TABLE 1. Continued
Author Year
Number of 
patients
Risk Factor/s
OR (95% 
Confidence Interval)
p-value Endpoint/s
Gupta et al [25]
Ozden et al [38]
Kristal et al [12]
Laven et al [16]
Temml et al [86]
Tomita et al [87]
Hammarsten et al [13]
Kupelian et al [32]
Hong et al [35]
2006
2007
2007
2008
2009
2009
2009
2009
2010
1,206
78
5,667
27,858
2,371
1,511
159
1,899
538
DM
Metabolic syndrome 
Metabolic syndrome
Body mass index 
  (≥35 vs. ＜25 kg/m
2)
Waist-hip ratio
  (≥1.05 vs ＜0.95%)
DM
Waist-hip ratio
  (＞0.98 vs. ＜0.90%)
Metabolic syndrome
Medication for DM type II
Medication for hyperten-
sion
Medication for hyperlipi-
demia
Fasting insulin 
Lean body mass
Metabolic syndrome 
Metabolic syndrome 
1.5 (1.2-1.8)
1.2 (0.9-1.6)
Direct relationship
1.2 (0.9-1.6)
1.3 (1.0-1.8)
0.9 (0.6-1.2)
1.2 (1.1-1.4)
No relationship
1.9 (1.1-3.2)
1.5 (1.0-2.1)
1.6 (1.0-2.5)
Direct relationship
Direct relationship
1.7 (1.2-2.4)
No relationship
0.004
0.1
0.01
0.01
0.02
0.3
＜0.05
0.8
-
-
-
0.02
0.03
-
0.3
BPH
Annual BPH growth rate
LUTS
Moderate-sever LUTS
LUTS
LUTS
Prostate gland volume
LUTS
LUTS
BPH: benign prostatic hyperplasia, DM: diabetes mellitus, LUTS: lower urinary tract symptoms
TABLE 2. Definition of metabolic syndrome according to the 
National Cholesterol Education Program adult treatment panel
III (2005 revision)
Criteria
a
1. Abdominal obesity (for men, waist circumference ＞102 cm)
2. Hypertriglyceridemia (＞1.69 mmol/l; ＞150 mg/dl) or treat-
ment
3. Low high-density lipoprotein cholesterol (for men, ＜1.04 mmol/l;
＜40 mg/dl) or treatment
4. High blood pressure (＞130/85 mmHg) or treatment
5. High fasting glucose (＞6.1 mmol/l; ＞110 mg/dl) or treatment
a: the presence of three or more pathologies is necessary to make
a diagnosis of metabolic syndrome
BASIC SCIENCE AND EPIDEMIOLOGIC 
EVIDENCE
1. Obesity
Several anthropometric measures have been used to define 
obesity, including waist circumference, waist-to-hip ratio, 
and body mass index (BMI). Giovannucci et al examined 
the data of 25,892 men who participated in the Health 
Professionals Follow-up Study (HPFS) and observed that 
patients with an obese waist circumference (＞109 cm) had 
a 2.4-fold higher risk (p＜0.001) of being surgically treated 
for BPH than did those with a nonobese waist circum-
ference (＜89 cm) [8]. 
　Dahle et al examined the relationship between 
waist-to-hip ratio (examined as quartiles) and LUTS in 502 
Chinese men. In their analyses [9], individuals with a 
waist-to-hip ratio of ≥92% (highest quartile) had a 2.0-fold 
(p=0.01) higher risk of BPH (defined as symptomatic en-
larged prostate requiring surgery) compared with their 
counterparts with a waist-to-hip ratio of ≤85% (lowest 
quartile). In the same report, no significant relationship 
was observed between BMI and BPH (p=0.1). The authors 
attributed this observation to the limited variation in BMI 
among study subjects (mean: 22.3 kg/m
2 for BPH cases vs 
21.9 kg/m
2 for controls; p=0.1). In fact, only 4% of the study 
subjects were overweight. Nevertheless, even in such a 
lean population, the waist-to-hip ratio was an important 
independent predictor of BPH. 
　Parsons et al observed that men with BMI ≥35 kg/m
2 had 
a 3.5-fold higher risk of harboring a large prostate (＞40 ml) 
than did their counterparts with a BMI ＜25 kg/m
2 [10]. 
Seim et al examined the data of 21,694 male residents of 
Norway and found that both BMI (odds ratio [OR]: 1.4) and 
waist-to-hip ratio (OR: 1.3) were significant predictors of 
moderate to severe LUTS [11], defined as an International 
Prostate Symptom Score (IPSS) of ≥8. Kristal et al further 
corroborated these observations in 5,677 participants of 
the Prostate Cancer Prevention Trial. In this cohort [12], 
men with BMI ≥35 kg/m
2 had a 1.2-fold higher risk of de-
veloping LUTS (defined as IPSS ≥15 or a LUTS-specific 
treatment) compared with their counterparts with BMI 
＜25 kg/m
2. Several other investigators corroborated the 
significant direct relationship between obesity and BPH/ 
LUTS [4,13-16]. 
　Taken together, it appears that obesity predisposes pa-
tients to a higher risk of BPH/LUTS. This may be due to 
the development of insulin resistance and secondary hy-Korean J Urol 2011;52:507-516
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perinsulinemia [17-19] or to the increased estrogen-to-an-
drogen ratio [8]. It is noteworthy that the association be-
tween obesity and BPH/LUTS was stronger for patients 
with severe symptoms requiring surgery (OR: 2.0-2.4) [8,9] 
than for those who reported moderate-to-severe LUTS 
(OR: 1.2-1.4) and may indicate a dose-response relation-
ship. Finally, the relationship between obesity and BPH/ 
LUTS was observed in different races and ethnicities (i.e., 
American, European, and Asian), indicating its genera-
lizability. 
2. Dyslipidemia
Similar to obesity, the relationship between BPH and dys-
lipidemia has been documented in several studies. 
R a h m a n  e l  a l  o b s e r v e d  t h a t  p r o s t a t e  w e i g h t  w a s  s i g -
nificantly higher in hyperlipidemic rats than in controls 
(mean: 2.6 vs 1.4 g; p＜0.001) [20]. Vikram et al conducted 
a longitudinal study over 12 weeks and reported that rats 
fed a high-fat diet had a significantly higher prostate 
weight than did controls [21]. These observations were fur-
ther corroborated by Escobar et al in another rat model [22]. 
　In addition to animal models, the relationship between 
BPH and dyslipidemia has been documented in epidemio-
logic studies. Hammarsten et al [14] examined the data of 
158 men and reported that individuals with a low level of 
high-density lipoprotein (HDL) cholesterol (＜1.18 mmol/l) 
had a larger prostate volume (mean: 49.0 vs 39.0 ml; 
p=0.002) and a higher annual BPH growth rate (mean: 1.02 
vs 0.78 ml/y; p=0.006) than did individuals with a high level 
of HDL cholesterol (≥1.18 mmol/l). In a subsequent report, 
Hammarsten and Högstedt corroborated these findings in 
a larger sample (n=307) [4]. Nandeesha et al observed that 
men with BPH had a significantly higher total cholesterol 
(mean: 4.5 vs 4.2 mmol/l; p＜0.05) and low-density lip-
oprotein (LDL) cholesterol levels (mean: 2.8 vs 2.2 mmol/l; 
p＜0.001) than did men without BPH [23]. The same au-
thors observed that the level of HDL cholesterol was sig-
nificantly lower in men with BPH than in those without 
BPH (mean: 0.9 vs 1.2 mmol/l; p＜0.001). 
　Conversely, in the Rancho Bernardo study, Parsons et 
al observed no overall association between LDL cholesterol 
and BPH (p=0.2) [24]. However, when men were stratified 
according to diabetes status, individuals with diabetes who 
had the highest LDL cholesterol had a 4-fold (95% con-
fidence interval [CI]: 1.3-12.6; p=0.02) higher risk of report-
ing BPH (defined as a history of prostate surgery other than 
for cancer or physician-diagnosed BPH) than did those 
with the lowest LDL cholesterol (＞133 mg/dl vs ＜110 
mg/dl). This observation suggests that dyslipidemia may 
interact with other components of MetS to increase BPH 
risk [24]. This may at least partially explain why other in-
vestigators observed no significant relationship between 
dyslipidemia and BPH/LUTS [25-27].
3. Hypertension
Hypertension was also associated with BPH/LUTS in sev-
eral animal models and epidemiologic studies. Golomb et 
al reported that spontaneously hypertensive rats develop 
BPH-like features with aging in the absence of any in-
ductive exogenous agents [28]. Conversely, their normo-
tensive counterparts did not develop such features. Ham-
marsten et al examined the data of 158 Swedish men re-
ferred to one center [14]. They reported that individuals 
with treated hypertension had a larger prostate volume 
(mean: 51.0 vs 44.0 ml; p=0.003) and higher annual BPH 
growth rate (mean: 1.06 vs 0.90 ml/y; p=0.002) than did 
controls. Similarly, Joseph et al reported that men with a 
history of hypertension had a 1.5-fold (95% CI: 1.1-2.1) 
higher risk of moderate-to-severe LUTS (defined as an 
American Urological Association Symptom Index [AUASI] 
of ≥8) compared with their counterparts without a history 
of hypertension [15]. Rohrman et al examined the data 
from 2,372 participants in the Third National Health and 
Nutrition Examination Survey (NHANES III) [29]. They 
reported that men with a history of hypertension had sig-
nificantly higher odds of LUTS than did their counterparts 
without such a history (OR: 1.8; 95% CI: 1.2-2.6).
4. Insulin resistance
Insulin resistance represents another important compo-
nent of MetS. To tackle the decreased responsiveness of in-
sulin-sensitive tissues toward insulin, β-cells secrete more 
insulin and hence hyperinsulinemia is observed. These 
hormonal abnormalities may play an important role in the 
development of BPH/LUTS. Vikram et al reported an aug-
mented prostatic epithelial cell proliferation in insulin-re-
sistant rats [21]. The same authors showed that an induced 
status of hypoinsulinemia led to a dramatic decrease in the 
size of the prostate gland [30]. These observations were cor-
roborated by Ikeda et al in another animal model [31]. 
　At an epidemiologic level, Hammareston and Högstedt 
[4] addressed the relationship between fasting plasma in-
sulin and BPH. In their cohort, men in the highest quartile 
of plasma fasting insulin (＞13 mU/l) had a significantly 
larger prostate volume (mean: 61.0 vs 45.0 ml; p=0.009) 
and higher annual BPH growth rate (mean: 1.49 vs 0.84 
ml/y; p=0.01) than did men in the lowest quartile of plasma 
fasting insulin (＜7 mU/l). In the Flint Men’s Health Study, 
individuals with a history of diabetes had twice the risk 
(OR: 2.0; 95% CI: 1.5-2.6) of suffering from moder-
ate-to-severe LUTS (defined as an AUASI ≥8) as did their 
counterparts without a history of diabetes [15]. Seim et al 
evaluated the data of 21,694 individuals who participated 
in the second Nord-Trondelag Health Study and reported 
that men with diabetes were more likely to have an IPSS 
≥8 than were their nondiabetic counterparts (OR: 1.3; 95% 
CI: 1.1-1.5) [11]. Similarly, Nandeesha et al reported that 
the level of fasting serum insulin was significantly higher 
in men with BPH than in controls (mean: 237.4 vs 134.7 
pmol/l; p＜0.001) [23]. In a recent report, Hammarsten et 
al confirmed the relationship between fasting serum in-
sulin and prostate volume in a multicentric study (β co-
efficient: 0.2; p=0.02) [13].Korean J Urol 2011;52:507-516
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5. Metabolic syndrome
Several criteria have been used to define MetS. Hammars-
ten et al defined MetS as having one or more of the following 
conditions: non-insulin-dependent diabetes mellitus, hy-
pertension, obesity, high insulin level, and low HDL choles-
terol [14]. They reported that men with MetS had a larger 
prostate volume (mean: 49.0 vs 28.5 ml; p=0.003) and a 
higher annual BPH growth rate (1.01 vs 0.69 ml/y; p=0.002) 
than did men without MetS. Rohrmann et al defined MetS 
as having at least three of the following five components 
[29]: (1) waist circumference ＞102 cm; (2) triglyceride con-
centration ≥1.69 mmol/l; (3) HDL cholesterol level ＜1.03 
mmol/l; (4) systolic blood pressure ≥130 mmHg, diastolic 
blood pressure ≥85 mmHg, or current use of blood pressure 
medication; and (5) fasting glucose concentration ≥6.1 
mmol/l or current use of oral diabetes medication or insulin. 
Additionally, they used a second, more specific definition 
that included components 1-3 but only in men who reported 
the use of blood pressure medication and men who used oral 
diabetes medication or insulin. 
　Rohrmann et al defined LUTS as having at least three 
of the following four urinary symptoms: nocturia, incom-
plete bladder emptying, weak stream, and hesitancy [29]. 
They reported that MetS was not statistically significantly 
associated with LUTS (OR: 1.2; 95% CI: 0.8-1.7). However, 
the OR was elevated in men with at least four components 
of MetS (OR: 1.6; 95% CI: 1.0-2.6) compared with men who 
had fewer components. Similarly, when the more specific 
definition of MetS was used, a significant association was 
evident between MetS and LUTS (OR: 1.8; 95% CI: 1.1-2.9). 
However, the cohort of this report [29] was restricted to men 
aged ≥60 years and included only four of the seven urologic 
symptoms that make up the AUASI. 
　To address the aforementioned limitations, Kupelian et 
al reexamined the relationship between MetS and LUTS 
in 1,899 men who participated in the Boston Area 
Community Health Survey [32]. They defined MetS ac-
cording to the Adult Treatment Panel III guidelines as the 
presence of three or more of the following five character-
istics: (1) waist circumference ＞102 cm; (2) systolic blood 
pressure  ≥130 mmHg, diastolic blood pressure ≥85 
mmHg, or antihypertensive medication use; (3) HDL cho-
lesterol ＜40 mg/dl or lipid medication use; (4) self-reported 
type 2 diabetes or increased blood sugar or diabetes medi-
cation use; and (5) triglycerides ＞150 mg/dl. In multi-
variable analyses that adjusted for age, race, socio-
economic status, physical activity, alcohol consumption, 
smoking, and LUTS medication, MetS emerged as an in-
dependent predictor of moderate-to-severe LUTS, which 
was defined as an AUASI ≥2 (OR: 1.7; 95% CI: 1.2-2.4). 
　Although several investigators have observed a sig-
nificant relationship between BPH/LUTS and MetS or one 
of its components, others have argued against these 
observations. Seitter and Barrett-Connor [33] reported no 
relationship between BMI and the rate of surgery for BPH. 
Meigs et al examined the data of 1,019 men who partici-
pated in the Massachusetts Male Aging Study and ob-
served that obesity and blood pressure were not sig-
nificantly related to subsequent clinical BPH development 
within a mean follow-up of 8.8 years [34]. Similarly, Hong 
et al observed no significant difference in the IPSS between 
men with and those without MetS (mean: 5.03 vs 5.40; 
p=0.3) [35]. 
　In summary, it appears that MetS and its individual 
components may predispose patients to a higher risk of 
BPH/LUTS. However, this observation should be consid-
ered with caution for several reasons. The aforementioned 
reports defined the examined predictors in several differ-
ent ways, and this variation may have affected the strength 
and significance level of their relationships with the exam-
ined endpoint. Moreover, the lack of consensus on the exact 
definition of MetS makes it more difficult to document the 
impact of this condition on the examined endpoint, namely, 
BPH/LUTS. The latter was also defined in several ways 
that ranged from a simple enlargement of the prostate 
gland to severe LUTS requiring surgery. Finally, different 
populations may have different genetic profiles, nutri-
tional habits, and environmental risk factors. All of these 
variables may affect the potential relationship between 
MetS and BPH/LUTS.
HYPOTHESIZED MECHANISMS 
1. Hyperinsulinemia and autonomic hyperactivity
Hyperinsulinemia is one of the components of MetS. 
Hyperinsulinemia is associated with increased sym-
pathetic activity via enhanced glucose metabolism in ven-
tromedial hypothalamic neurons [36]. This may contribute 
to an increase in the activation of the α-adrenergic path-
way, which may in turn increase smooth muscle con-
traction throughout male genitourinary tract structures, 
including the prostate, the bladder neck, and the urethra, 
thereby contributing to LUTS [37,38]. 
　This concept has been studied in both animal models and 
human subjects. In the rat model, McVary et al observed 
an association between autonomic neural input to the pros-
tate and the prostatic growth rate such that the absence 
of this input resulted in regression of the gland volume [39]. 
In a subsequent report, the same authors investigated the 
relationship between autonomic tone and LUTS secondary 
to BPH in 38 human subjects of the Medical Therapy of 
Prostatic Symptoms trial [40]. They reported that markers 
of autonomic hyperactivity (blood pressure elevation, 
heart rate elevation, and elevated serum or urine catechol-
amines) were positively associated with subjective mark-
ers of LUTS (AUASI, quality of life score, and BPH Impact 
Index). Moreover, in multivariable analyses, plasma nor-
epinephrine emerged as an independent predictor of the 
prostatic transition zone volume [40]. 
　Using data from the same trial, Roehrborn et al showed 
that α-blockade alone may be sufficient in treating the 
symptoms of men with small prostate volume (＜20 ml) 
[41], whereas men with larger prostates benefited more 
from a combination of α-blockade and 5α-reductase in-Korean J Urol 2011;52:507-516
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hibitor therapy. These findings corroborate what has been 
reported by McVary et al and imply that autonomic hyper-
activity may be an important determinant of LUTS in men 
with BPH [39,40]. Several other investigators confirmed 
the relationship between increased autonomic activity and 
BPH/LUTS [42,43].
　Hyperinsulinemia is also associated with an increase in 
the level of free insulin-like growth hormone 1 (IGF-1) [44]. 
Several studies reported that the increase in the level of 
IGF-1 predisposes patients to a higher risk of BPH [45-47]. 
Consequently, hyperinsulinemia may also indirectly in-
crease the risk of BPH by increasing the level of IGF-1. 
2. Impaired nitric oxide and nitric oxide synthase activity
MetS has been associated with elevated levels of C-reactive 
protein (CRP) as well as other inflammatory markers 
[48-50]. This may reduce nitric oxide (NO) synthesis in en-
dothelial cells [51]. Similarly, other components of MetS, 
namely, hyperglycemia and dyslipidemia, are associated 
with increased free radical production [52]. The latter may 
inhibit NO synthesis via activation of the protein kinase 
C pathway that may ultimately lead to decreased NO syn-
thase (NOS) activation [52]. 
　The diminished prostatic NO/NOS activity may lead to 
increased smooth muscle proliferation, prostatic enlarge-
ment, and subsequent LUTS [37]. Takeda et al examined 
tissue preparations of human and canine prostates and ob-
served that NO plays an important role in mediating 
smooth muscle relaxation within the gland [53]. Conse-
quently, the impairment of NO activity may contribute to 
voiding dysfunction in LUTS patients by impairing muscu-
lar relaxation. 
　Bloch et al performed a histochemical and ultra-
structural examination of the prostate tissue with the in-
tent of determining the location of endothelial and neuro-
nal NOS in human prostate [54]. Their study resulted in 
several important findings. First, they observed that NO 
plays an important role in the autonomic innervation of all 
compartments of prostatic tissue. Second, they found that 
in obstructive BPH, the nitrergic innervation is reduced 
compared with that in normal prostate tissue. They con-
cluded that the increased muscular tone in patients with 
BPH may be attributed to strengthened α-adrenergic stim-
ulations as well as to decreased nitrergic innervation.
　Apart from smooth muscle relaxation, NO has crucial 
functions in maintaining vascular health. It defends 
against the initiation of atherosclerosis by inhibiting adhe-
sion of platelets and leukocytes to the vascular wall. It de-
creases the proliferation of vascular smooth muscles [52]. 
Bloch et al [54] suggested that NO has an important role 
in the regional circulation of the prostate gland; thus, im-
paired NO/NOS activity may lead to endothelial dysfunc-
tion and atherosclerosis. Numerous animal studies have 
linked atherosclerosis and chronic ischemia to bladder and 
prostatic changes [37]. Rabbits with induced pelvic athero-
sclerosis developed bladder fibrosis, smooth muscle atro-
phy, and decreased bladder compliance [55] as well as 
chronic prostatic ischemia with resultant stromal and cap-
sular fibrosis, glandular cystic atrophy, impaired smooth 
muscle relaxation, and increased prostatic weight [56,57].
3. The Rho kinase system
The Rho kinase system plays an important role in the main-
tenance of tonic contraction or high basal tone and may con-
tribute to prostate contractility [58]. Specifically, the Rho 
kinase system causes smooth muscle contraction by mod-
ifying the calcium sensitivity of the contractile machinery 
[37,59]. This appears to be mediated by the inhibition of my-
osin-light chain phosphatase, which promotes myosin- 
light chain phosphorylation and contraction through ac-
tin-myosin interaction [37,60,61]. NO counteracts this by 
favoring the active form of myosin–light chain phosphatase 
[61]. In contrast, α-adrenergic activity stimulates the Rho 
kinase pathway [37]. Similarly, the higher levels of inter-
leukin (IL)-8 and the vasoconstrictor endothelin-1, which 
are usually observed in men with MetS, may lead to an in-
creased Rho kinase system activity [37,50,52,58,59,62-64]. 
All of these MetS components (ie, impaired NO activity, au-
tonomic hyperactivity, elevated IL-8 level, and elevated 
endothelin-1 level) may favor the activity of the Rho kinase 
system and may in turn result in a higher prostate con-
tractility and LUTS. 
4. Proinflammatory status
Metabolic syndrome is associated with proinflammatory 
status. This is demonstrated by elevated levels of CRP, 
IL-1β, IL-6, and tumor necrosis factor α (TNF-α) in men 
with MetS [48-50,62]. Obesity induces adipose cell enlarge-
ment and chemokine release, leading to macrophage in-
filtration of adipose tissue [65]. Macrophage infiltration 
further perpetuates the proinflammatory state and may 
account for the adipose secretion of adipokines such as 
IL-1β, IL-6, IL-8, CRP, and TNF-α [65-68]. Macrophage 
and T-lymphocyte infiltrates are commonly found in pros-
tate tissue removed during open prostatectomy and tran-
surethral resection of the prostate [69]. Similarly, several 
proinflammatory cytokines are upregulated in BPH, sug-
gesting an immunologic etiology for the inflammation [69]. 
Cytokines IL-6 and IL-8, for example, are elevated in MetS 
and may contribute to inflammation in BPH/LUTS, as both 
can be secreted by stromal cells with cytokine stimulation 
and both result in proliferation of prostatic tissues [70]. In 
patients with BPH, seminal IL-8 levels were positively cor-
related with LUTS via the IPSS [71]. 
5. Abnormalities of sex hormones
Sex hormonal changes may further contribute to the link-
age of BPH/LUTS and MetS. Men with MetS as well as 
those with LUTS/BPH may have lower androgen and high-
er estrogen levels. Rohrmann et al analyzed 260 indivi-
duals from NHANES III and reported that elevated estro-
gen levels and molar estradiol/testosterone ratios as well 
as lower androstanediol glucuronide (a metabolite of dihy-
droxytestosterone [DHT]) levels were associated with Korean J Urol 2011;52:507-516
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greater LUTS risk [72]. Similarly, Schatzl et al found a di-
rect correlation between elevated estradiol levels and pro-
static volume determined with transrectal ultrasound 
[73]. In the Physicians’ Health Study, elevated estradiol 
level was an independent predictor of BPH surgery in men 
with low testosterone or DHT levels [74]. Haider et al stud-
ied hypogonadal men and observed an improvement in 
IPSS and postvoiding volume after a period of treatment 
with testosterone undecanocate [75]. Similarly, Kalin-
chenko et al treated 30 hypogonadal men with either tes-
tosterone gel or testosterone undecanoate and reported 
IPSS improvement in both groups [76]. However, the regu-
lation and impact of sex hormones on prostatic growth and 
BPH/LUTS is quite complex, and not all authors found evi-
dence of such definitive relationships [77,78].
　In addition to the aforementioned mechanisms, other 
unknown mechanisms may contribute to the relationship 
between MetS and BPH/LUTS. Moreover, the afore-
mentioned mechanisms may interact and articulate with 
each other. The mechanisms that regulate the potential re-
lationship between MetS and BPH/LUTS are quite com-
plex and require further scientific inquiry.
PHYSICAL ACTIVITY, METABOLIC SYNDROME, 
AND BENIGN PROSTATIC HYPERPLASIA
If MetS is indeed associated with an increased risk of 
BPH/LUTS, then it can be hypothesized that physical ac-
tivity, which is known to decrease the cardiovascular mor-
bidity risk associated with MetS, may also decrease the risk 
of BPH/LUTS. Several epidemiologic data support this 
hypothesis. Platz et al examined the data of 30,634 men 
who participated in the HPFS and observed that physical 
activity was associated with lower risk of total BPH (OR: 
0.75; 95% CI: 0.64-0.90; p＜0.001), surgery for BPH (OR: 
0.76; 95% CI: 0.64-0.90; p＜0.001), and symptomatic BPH 
(OR: 0.75; 95% CI: 0.64-0.87; p＜0.001) [79]. 
　Similarly, Rohrmann et al analyzed the data of 2797 in-
dividuals who participated in NHANES III [80] and re-
ported that men with the highest rate of physical activity 
(highest quartile) had almost half the risk of suffering from 
LUTS (defined as having three of the following four urinary 
symptoms: nocturia, incomplete bladder emptying, weak 
stream, and hesitancy) as did their counterparts who re-
ported no physical activity (OR: 0.49; 95% CI: 0.29-0.84; 
p=0.05). In an interesting report, Dal Maso et al observed 
that “heavy” occupational activity (eg, farmers, con-
struction workers) led to a lower risk of developing BPH 
than did sedentary occupational activity [81]. However, 
not all investigators observed a significant inverse rela-
tionship between physical activity and BPH/LUTS [82]. 
Nonetheless, a recent meta-analysis that examined the da-
ta from eight reports, with a total of 35,675 patients in-
cluded, confirmed that physical activity reduces the risk of 
BPH/LUTS [83]. 
　In summary, it appears that sustained physical activity 
reduces the overall risk of BPH/LUTS in men. However, 
none of the aforementioned studies exclusively addressed 
patients with MetS. Consequently, the real benefit of phys-
ical activity in patients with MetS and how it may modify 
the risk of BPH/LUTS in these patients has yet to be 
clarified. In addition to physical activity, other lifestyle 
changes, such as dietary strategies to reduce postprandial 
glucose and triglyceride spikes and to increase the intake 
of dietary antioxidants, potassium, and omega-3 fatty 
acids may be helpful in reducing the incidence of metabolic 
syndrome [84] and its association with BPH/LUTS. 
CONCLUSIONS
Numerous reports have documented a direct and sig-
nificant relationship between components of MetS and the 
BPH/LUTS complex. However, differences in the strength 
and the statistical significance level of this relationship 
were observed. These differences may originate from the 
use of different descriptions to define the examined risk fac-
tors and endpoints as well as differences in the character-
istics of the examined populations. Although the associa-
tion between these two pathologic conditions seems plau-
sible, the underlying mechanisms that create such an asso-
ciation need to be clarified. 
　Further study of the interplay between MetS and BPH/ 
LUTS may provide new insight into the cause of these dis-
eases and novel targets for their treatment and prevention. 
In the meantime, obesity, dyslipidemia, hypertension, and 
diabetes should be considered risk factors when advising 
patients with LUTS. Modifications of lifestyle, such as in-
creased physical activity and dietary strategies, may be of 
benefit for these individuals to improve their LUTS.
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